Drug intelligence / Profile preview

STACT

Development stage: Unknown
Lead developer: Actym Therapeutics
Modality: Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Gene Silencing → Gene Therapies, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Gene Editing → Gene Therapies, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Gene Addition/Replacement → Gene Therapies
Administration: Intravenous

Overview

STACT (S. Typhimurium-Attenuated Cancer Therapy) is a patent-protected, microbial-based immunotherapeutic technology platform developed by Actym Therapeutics for treating solid tumors. [3-13, 3-14] The platform utilizes a genetically engineered, attenuated strain of *Salmonella Typhimurium* as a vehicle that can be administered systemically. [1, 2] In preclinical studies, STACT was shown to specifically enrich in solid tumors rather than healthy tissue. [3-15, 3-16] Once inside the tumor, the bacteria deliver multiple immuno-modulatory payloads directly to tumor-resident immune cells, particularly phagocytic antigen-presenting cells (APCs), activating both innate and adaptive immunity. [2, 3-15, 3-16, 6] This approach enables the local delivery of potent therapeutic combinations that would be too toxic for systemic administration via conventional methods. [1, 3-17] The lead clinical candidate from this platform is ACTM-838, which delivers an engineered IL-15plex and a STING agonist. [2, 3]

Other names: S. Typhimurium-Attenuated Cancer Therapy

Targets

IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)STING (Stimulator of interferon genes protein)

Beyond the preview

Go deeper on STACT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STACT.

Explore the full profile